Hagihara M, Shimura T, Takebe K, Munkhbat B, Hosoi K, Kagawa T, Watanabe N, Matsuzaki S, Yamamoto K, Sato K, Tsuji K
Department of Transplantation Immunology, Tokai University School of Medicine, Kanagawa, Japan.
J Gastroenterol. 1997 Jun;32(3):338-43. doi: 10.1007/BF02934490.
Soluble HLA-class I and CD8 molecules were determined by sandwich ELISA in patients with viral-induced hepatic disorders. As a whole, the patients with hepatic disorders (acute hepatitis: AH; chronic hepatitis: CH; liver cirrhosis: LC; hepatocellular carcinoma: HCC) showed higher sHLA-class I and sCD8 levels than normal controls (P < 0.001). AH patients had the highest sHLA-class I levels (mean, 3513 +/- 2112 ng/ml), followed by CH (2896 +/- 1290 ng/ml), LC (2293 +/- 1266 ng/ml), and HCC (2221 +/- 1212 ng/ml) sCD8 levels wer highest in AH, followed by HCC, LC, and CH, in that order. Among histologically defined C virus-positive patients, sHLA-I levels were higher in those with chronic active hepatitis (CAH) 2A (3802 +/- 1124 ng/ml) than in those with chronic persistent hepatitis (CPH; 2200 +/- 711 ng/ml; P < 0.01), the levels then decreased as the disease progressed (CAH2B, 3564 +/- 1783 ng/ml, LC, 2376 +/- 1265 ng/ml). In contrast, sCD8 values showed little difference among the disorders. sHLA-class I levels showed a positive correlation with sCD8 values both in whole patients and in patients with AH (P < 0.01), but no correlation was shown, in any patients, with biochemical parameters such as GPT and GOT. These findings, taken together, suggest that hepatic destruction is not the only cause of sHLA-class I production, but that sHLA-class I levels, together with sCD8 levels, may reflect immunological activity in hepatic disorders.
采用夹心酶联免疫吸附测定法（ELISA）检测病毒感染所致肝脏疾病患者可溶性人白细胞抗原I类分子（sHLA - I）和CD8分子水平。总体而言，肝脏疾病患者（急性肝炎：AH；慢性肝炎：CH；肝硬化：LC；肝细胞癌：HCC）的sHLA - I和sCD8水平高于正常对照组（P < 0.001）。AH患者的sHLA - I水平最高（均值为3513 ± 2112 ng/ml），其次是CH（2896 ± 1290 ng/ml）、LC（2293 ± 1266 ng/ml）和HCC（2221 ± 1212 ng/ml）。sCD8水平在AH中最高，其次依次为HCC、LC和CH。在组织学确诊的丙型肝炎病毒阳性患者中，慢性活动性肝炎（CAH）2A患者的sHLA - I水平（3802 ± 1124 ng/ml）高于慢性持续性肝炎（CPH；2200 ± 711 ng/ml；P < 0.01），随着疾病进展水平逐渐降低（CAH2B为3564 ± 1783 ng/ml，LC为2376 ± 1265 ng/ml）。相比之下，sCD8值在不同疾病间差异不大。sHLA - I水平在所有患者及AH患者中均与sCD8值呈正相关（P < 0.01），但在任何患者中均与谷丙转氨酶（GPT）和谷草转氨酶（GOT）等生化指标无相关性。综合这些发现表明，肝脏破坏并非sHLA - I产生的唯一原因，但sHLA - I水平与sCD8水平可能共同反映肝脏疾病中的免疫活性。
